Home › Funds › Patient Capital Management, LLC › EXPE
Patient Capital Management, LLC position in EXPE
EXPEDIA GROUP INC · Consumer Discretionary
Patient Capital Management, LLC reported holding 167,131 shares of EXPE (EXPEDIA GROUP INC) in its Q3 2026 13F filing — a position valued at US$44.0M, representing 1.49% of its reported portfolio and ranking #24 among its reported holdings. Patient Capital Management, LLC has disclosed EXPE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Patient Capital Management, LLC's EXPE position evolved
Patient Capital Management, LLC first disclosed a stake in EXPE in Q3 2023 at 971,037 shares (US$100.1M). The position peaked in Q4 2023 at 935,490 shares, worth US$142.0M. Across 13 filings, Patient Capital Management, LLC increased the stake 0 time(s), trimmed it 10 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 167,131 shares valued at US$44.0M. Notable position changes include a 32% trim in Q4 2024 (shares fell 10% over the following quarter), a 37% trim in Q1 2025 (shares were roughly flat over the following quarter), a 30% trim in Q4 2025 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 971.04K | $100.08M | New |
| Q4 2023 | 935.49K | $142.00M | Reduce |
| Q1 2024 | 729.59K | $100.50M | Reduce |
| Q2 2024 | 715.98K | $90.21M | Reduce |
| Q3 2024 | 647.33K | $95.82M | Reduce |
| Q4 2024 | 442.43K | $82.44M | Reduce |
| Q1 2025 | 278.80K | $46.87M | Reduce |
| Q2 2025 | 261.86K | $44.17M | Reduce |
| Q3 2025 | 253.48K | $54.18M | Reduce |
| Q4 2025 | 176.28K | $49.94M | Reduce |
| Q1 2026 | 167.78K | $38.74M | Reduce |
| Q2 2026 | 167.81K | $42.94M | Hold |
| Q3 2026 | 167.13K | $44.02M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EXPE and 13F data
EXPE (EXPEDIA GROUP INC) is a Consumer Discretionary company. 42 other funds we track also report a position in EXPE — the largest reported positions include WINDACRE PARTNERSHIP LLC (US$1.00B), PAR CAPITAL MANAGEMENT INC (US$485.1M), Alkeon Capital Management (US$467.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EXPE
- WINDACRE PARTNERSHIP LLC 3.91M sh · $1.00B · Q2 2026
- PAR CAPITAL MANAGEMENT INC 1.90M sh · $485.11M · Q2 2026
- Alkeon Capital Management 1.83M sh · $467.05M · Q2 2026
- LYRICAL ASSET MANAGEMENT LP 1.43M sh · $376.76M · Q3 2026
- Pacer Advisors, Inc. 1.42M sh · $362.29M · Q2 2026
More on Patient Capital Management, LLC
FAQ
How long has Patient Capital Management, LLC held EXPE?
Patient Capital Management, LLC has disclosed EXPE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Patient Capital Management, LLC's current position in EXPE?
As of Q3 2026, Patient Capital Management, LLC holds 167.13K shares of EXPE (EXPEDIA GROUP INC), valued at $44.02M, representing 1.49% of its reported portfolio and ranking #24.
Has Patient Capital Management, LLC been buying or selling EXPE?
In the latest 13F filing (Q3 2026), Patient Capital Management, LLC held unchanged its position in EXPE. The position peaked in Q4 2023 at 935.49K shares.
Which other funds hold EXPE?
Other major institutional holders of EXPE include WINDACRE PARTNERSHIP LLC, PAR CAPITAL MANAGEMENT INC, Alkeon Capital Management, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.